For patients with secondary HPT on dialysis
Share Page
Change Text Size A A A

Do you need help paying for Sensipar®?

Select your insurance type to see which programs may help with your out of pocket costs.

To learn more about

Amgen Assist®,

our reimbursement
and coverage support service,
click here >
Medicare Part D Dual-Eligible/LIS*
  • Your co-pay for Sensipar® should be $6.602,3 or less.1
Standard Medicare Part D†
  • You may be eligible for help from an independent co-pay foundation.
Private Insurance (Commercial)
  • The Sensipar® Pharmacy Card can lower your Sensipar® co-pay to $5.00, if you qualify.
Self Pay
  • The Safety Net Foundation can help eligible patients receive Sensipar® at no cost.

If you aren’t sure which type of insurance you have, please call Amgen Assist® 1-800-272-9376 or visit www.AmgenAssist.com for help.

If you have any problems paying for your Sensipar® prescription at the pharmacy, discuss this with your dialysis care team at your next session.
To learn more about

Amgen Assist®,

our reimbursement
and coverage support service,
click here >
* The dual-eligible section includes Medicare/Medicaid, other Medicare patients who qualify for the Part D LIS, and government assistance. These patients have reduced cost sharing and are not subject to the coverage gap.
† Standard Medicare Part D includes those who have purchased a Part D prescription plan but who have sufficient assets or income that disqualify them from receiving Medicaid or the LIS.
LIS = low-income subsidy.

Sensipar® is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

  • Sensipar® treatment should not be started if you have low calcium levels. Ask your doctor about the normal ranges.
  • Before starting Sensipar®, tell your doctor if you are taking medication to prevent seizures or have had seizures in the past. Report any seizure episodes while on Sensipar® therapy.
  • Very infrequent cases of low blood pressure, worsening heart failure, and/or abnormal heart rhythm (arrhythmia) have been reported in patients with impaired heart function taking Sensipar®.
  • While on Sensipar®, your doctor should perform repeated blood tests to monitor calcium, phosphorus, and intact parathyroid hormone (iPTH) levels. Very low and very high levels of PTH should be avoided to help maintain bone health. Very low levels (iPTH < 100 pg/mL) of PTH may cause a condition your doctor may refer to as adynamic bone disease.
  • Patients with moderate to severe liver impairment should be monitored throughout treatment with Sensipar®.
  • Tell your doctor if you experience any muscle spasms, aches or cramping, tingling in your limbs, or seizures.
  • In clinical trials, the most common side effects reported in patients were nausea, vomiting, and diarrhea.

If you have any questions about this information, be sure to discuss them with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (332-1088).

Reference: 1. Centers for Medicare & Medicaid Services website. Announcement of calendar year (CY) 2013 Medicare Advantage capitation rates and Medicare Advantage and Part D payment policies and final call letter. Available at: http://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/downloads/Announcement2013.pdf. Accessed November 1, 2012. 2. National Payor Mix/p. 6. 3. CMS 2013 Part D Announcement/p 39/Part D Benefit Parameters Table.
Return to Top
Back to top